CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-17). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2709 · Search date 2026-08-17 · Methodology v0.7

Genomic-metabolomic personalized diet,
does it really help with Greater fat-mass loss than a generic healthy diet?

30-Second Summary
D
Evidence Grade D · 30 · Safety acceptable
Genomic-metabolomic personalization did not reduce fat mass more than a generic healthy diet
No major adverse-event signal was reported for the study diets. Medical diets, allergies, and treatment-related restrictions require individualized professional assessment rather than reliance on a testing algorithm.
What the
research shows
The grade is D with 30 points. In PREVENTOMICS, 10-week fat-mass change was -2.1 kg with personalization and -2.0 kg with a generic healthy diet; the adjusted between-group difference was -0.1 kg (95% CI -1.2 to 0.9, P=.77). Both groups lost weight, but omics-based personalization added no benefit.
What the
ads claim
The platform genuinely classified metabolic profiles and changed advice, but that added personalization did not reduce fat mass more than the healthy control diet.
*

Useful facts when choosing a product

  • The platform used 51 blood and urine metabolic biomarkers and 35 salivary SNPs.
  • Both groups received 12 of 21 weekly meals free for 10 weeks without instructions to restrict calories.
  • PMID 35351696 is the protocol and PMID 35839545 the main result; both report NCT04590989.
Gap Measurement · Verdict 2709 · D 30
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

This single-center Danish double-blind parallel trial randomized 100 participants, 49 versus 51. The BMJ Open protocol and Clinical Nutrition results are reports from the same NCT04590989 trial and count once. Primary fat-mass analysis used available data from 82 participants, 38 versus 44, excluding 18%. Enrollment below 200, 10-week duration, attrition above 15%, and available-data rather than complete randomized-group preservation are limitations. Public and university funding from EU Horizon 2020 and a university scholarship was confirmed.

02

Why this is classified as D (30)

The prespecified primary fat-mass outcome showed no personalization advantage in a single 100-person 10-week trial, giving D with 30 points.

Counterpoint. Other algorithms, longer follow-up, or prospectively specified biological subgroups remain separate questions.

Rejudgment record. Cross-check applied — Cross-checked NCT04590989, the BMJ Open protocol, and Clinical Nutrition results for one-trial identity, primary endpoint, 82-person analysis, interval, and public funding

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduces fat mass more than a generic healthy dietDThe adjusted difference was -0.1 kg and the interval included zero.
Weight loss within both healthy-diet programsCBoth groups lost weight, but no untreated control separated a common program effect.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Aldubayan MA, Pigsborg K, Gormsen SMO, Serra F, Palou M, Galmés S, Palou-March A, Favari C, Wetzels M, Calleja A, Rodríguez Gómez MA, Castellnou MG, Caimari A, Galofré M, Suñol D, Escoté X, Alcaide-Hidalgo JM, M Del Bas J, Gutierrez B, Krarup T, Hjorth MF, Magkos F. 2022 PREVENTOMICSSingle-center double-blind randomized parallel trial; same trial as the BMJ Open protocol44EU Horizon 2020 grant 818318 and a King Saud bin Abdulaziz University PhD scholarshipChange in DXA fat mass at 10 weeks-2.1 vs -2.0 kg; adjusted between-group difference -0.1 kg (95% CI -1.2 to 0.9), P=.77Single publicly funded null trial on the prespecified primary endpoint
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-17).

Aldubayan MA, Pigsborg K, Gormsen SMO, Serra F, Palou M, Galmés S, Palou-March A, Favari C, Wetzels M, Calleja A, Rodríguez Gómez MA, Castellnou MG, Caimari A, Galofré M, Suñol D, Escoté X, Alcaide-Hidalgo JM, M Del Bas J, Gutierrez B, Krarup T, Hjorth MF, Magkos F. A double-blinded, randomized, parallel intervention to evaluate biomarker-based nutrition plans for weight loss: The PREVENTOMICS study. Clin Nutr. 2022;41(8):1834-1844. PMID: 35839545. DOI: 10.1016/j.clnu.2022.06.032. NCT04590989.
checked
Aldubayan MA, Pigsborg K, Gormsen SMO, Serra F, Palou M, Mena P, Wetzels M, Calleja A, Caimari A, Del Bas J, Gutierrez B, Magkos F, Hjorth MF. Empowering consumers to PREVENT diet-related diseases through OMICS sciences (PREVENTOMICS): protocol for a parallel double-blinded randomised intervention trial to investigate biomarker-based nutrition plans for weight loss. BMJ Open. 2022;12:e051285. PMID: 35351696. DOI: 10.1136/bmjopen-2021-051285. NCT04590989.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-17 · Corrections: none

Cite this verdict

Genomic-metabolomic personalized diet x fat-mass reduction Evidence Grade D card
[Chamgap] Genomic-metabolomic personalized diet x fat-mass reduction — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/genomic-metabolomic-personalized-diet-fat-mass/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.